Tumor suppressor PLK2 may serve as a biomarker in triple-negative breast cancer for improved response to PLK1 therapeutics.
Gao Y, Kabotyanski EB, Shepherd JH, Villegas E, Acosta D, Hamor C, Sun T, Montmeyor-Garcia C, He X, Dobrolecki LE, Westbrook TF, Lewis MT, Hilsenbeck SG, Zhang XH, Perou CM, Rosen JM.
Gao Y, et al. Among authors: kabotyanski eb.
Cancer Res Commun. 2021 Dec;1(3):178-193. doi: 10.1158/2767-9764.crc-21-0106. Epub 2021 Dec 27.
Cancer Res Commun. 2021.
PMID: 35156101
Free PMC article.